Antisense Nucleic Acid Composition for Treating Neuromuscular Disorders
Summary
The European Patent Office published patent application EP3778895A1 for Nippon Shinyaku Co., Ltd. and National Center of Neurology and Psychiatry, covering antisense nucleic acid compositions for treating neuromuscular disorders. The patent application was published with international patent classifications in C12N, A61K, and C07H categories.
What changed
The EPO published patent application EP3778895A1 for antisense nucleic acid compositions. The application designates 31 European states including Germany, France, UK, Italy, Spain, Netherlands, and other EU/EEA countries. The invention relates to nucleic acid therapeutic compositions classified under C12N 15/113.
For pharmaceutical companies and biotechnology firms developing nucleic acid-based therapeutics, this patent establishes intellectual property rights in key European markets. Companies pursuing similar antisense technologies for neuromuscular or neurological disorders should assess potential infringement risks and consider licensing negotiations with the patent holders.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Review licensing opportunities for antisense technology
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTISENSE NUCLEIC ACID
Publication EP3778895A1 Kind: A1 Apr 01, 2026
Applicants
Nippon Shinyaku Co., Ltd., National Center of Neurology and Psychiatry
Inventors
ENYA, Yukiko, TONE, Yuichiro, TAKEDA, Shin'ichi, AOKI, Yoshitsugu
IPC Classifications
C12N 15/113 20100101AFI20210113BHEP A61K 31/712 20060101ALI20210113BHEP A61K 48/00 20060101ALI20210113BHEP A61P 21/00 20060101ALI20210113BHEP C07H 21/04 20060101ALI20210113BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.